Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Neurogene (NGNE) is now available.
Neurogene Inc. has reported promising safety and tolerability outcomes from its Phase 1/2 gene therapy trial for Rett syndrome, highlighting that its treatment, NGN-401, shows no serious adverse events or toxicity in patients. This update, revealed at a major gene and cell therapy conference, is a positive sign for investors and stakeholders looking for advancements in gene therapy treatments.
For a thorough assessment of NGNE stock, go to TipRanks’ Stock Analysis page.